National Clinical Pharmacist Training Base Faculty, Shanghai "Medical Garden New Star" Young Medical Talent, District-level Discipline Leader, and Outstanding Talent of the Chinese Pharmaceutical Association. Concurrently serves as Chair of the Youth Committee of the Cardiovascular Pharmacy Branch of the Chinese Association of Cardiothoracic Vascular Anesthesia, Vice Chair of the Youth Committee of the Hospital Pharmacy Special Committee of the Shanghai Pharmaceutical Association, Youth Member of the Hospital Pharmacy Special Committee of the Chinese Pharmaceutical Association, Secretary of the Yangtze River Delta Anticoagulation Pharmacist Alliance, and Secretary of the Shanghai Anticoagulation Pharmacist Alliance. Long-term engagement in the management and research of pharmacotherapy. Under the influence of the "research-oriented clinical pharmacist training" philosophy advocated by Director Lin Houwen, after years of rigorous scientific exploration, the clinical pharmacist team led by Gu Zhichun took the lead in establishing the "Innovative System for Pharmacotherapy Management of Multiple Chronic Diseases," achieving a series of innovative outcomes. Through the establishment of chronic disease pharmacotherapy management clinics, they independently developed easily promotable medication education items with independent intellectual property rights, and formulated service standards and standardized operating procedures for chronic disease pharmaceutical clinics; pioneered a pharmacotherapy management model from the perspective of optimal decision-making, established the first domestic "Municipal and Yangtze River Delta Hospital Anticoagulation Pharmacist Alliance," and independently developed the "Ai Kang Ning" intelligent pharmacotherapy decision-making and management system. Based on evidence-based research findings, the system achieves patient medication risk prediction, optimal regimen recommendation, individualized dose calculation, and full-process medication management, constructing a homogeneous and standardized service system for pharmacotherapy management of multiple chronic diseases, thereby enhancing the efficacy of pharmacotherapy management. Meanwhile, based on evidence-based pharmacy methods, they mined over 300 RCT studies and more than 500 health insurance data sets, completing 20 systematic reviews of medication regimens for chronic disease patients; applied discrete event simulation technology and fuzzy neural network deep learning technology to successfully predict medication risks of narrow therapeutic window drugs such as warfarin in chronic disease patients, and optimized model performance using a "balanced data strategy" to provide medication dosage recommendations for patients. The evidence-based rational drug use system constructed promotes guideline evidence updates, changes clinical medication recommendations, and enhances the level of evidence-based medication use. This system has been successfully applied in multiple medical institutions nationwide, achieving intelligent and homogeneous chronic disease pharmacotherapy management through tertiary-secondary-community hospital linkage, benefiting tens of thousands of chronic disease patients, significantly improving their medication awareness, satisfaction, and adherence, and realizing the transformation of pharmacotherapy management from traditional manual and fragmented approaches to intelligent, full-process, and information-based approaches, significantly enhancing the level of rational drug use management in China. Based on this system, over 100 research achievements have been published, 20 of which have been cited by medical guidelines in North America, Asia-Pacific, and China, and it has received the Gold Award and Silver Award in the Discipline Management Group of the "China Hospital Management Award," and the First Prize of the Science and Technology Progress Award of the Ministry of Education (ranked second). Gu Zhichun has presided over and participated in more than 10 national and provincial-level research projects focusing on anticoagulation evidence and anticoagulation management. As first or corresponding author, he has published over 100 SCI papers in authoritative journals in the field, including eClinicalMedicine, Clin. Gastroenterol. Hepatol., Int J Surg, Pharmacol. Res., and has been appointed as Associate Editor of a special issue of Frontiers in Pharmacology.